keyword
MENU ▼
Read by QxMD icon Read
search

LAMA LABA

keyword
https://www.readbyqxmd.com/read/29763411/characteristics-and-health-care-resource-use-of-subjects-with-copd-in-the-year-before-initiating-lama-monotherapy-or-lama-laba-combination-therapy-a-u-s-database-study
#1
Saurabh Nagar, Jeetvan Patel, Richard H Stanford
PURPOSE: To characterize subjects with chronic obstructive pulmonary disease (COPD) newly initiated on long-acting muscarinic antagonists (LAMA) or dual LAMA/long-acting β2-adrenergic agonist (LABA) therapy. DESIGN: This pilot/preliminary analysis was a retrospective crosssectional study of subjects with COPD from the Optum Impact National Managed Care Benchmark Database. METHODOLOGY: Subjects with at least one LAMA prescription in the index period (July 2008-June 2009) were included and stratified by treatment...
May 2018: Managed Care
https://www.readbyqxmd.com/read/29750142/single-inhaler-triple-therapy-in-symptomatic-copd-patients-fulfil-subgroup-analyses
#2
David M G Halpin, Ruby Birk, Noushin Brealey, Gerard J Criner, Mark T Dransfield, Emma Hilton, David A Lomas, Chang-Qing Zhu, David A Lipson
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2 -agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29747661/modelling-the-asthma-phenotype-impact-of-cigarette-smoke-exposure
#3
Maria G Belvisi, Katie Baker, Nicole Malloy, Kristof Raemdonck, Bilel Dekkak, Michael Pieper, Anthony T Nials, Mark A Birrell
BACKGROUND: Asthmatics that are exposed to inhaled pollutants such as cigarette smoke (CS) have increased symptom severity. Approximately 25% of adult asthmatics are thought to be active smokers and many sufferers, especially in the third world, are exposed to high levels of inhaled pollutants. The mechanism by which CS or other airborne pollutants alter the disease phenotype and the effectiveness of treatment in asthma is not known. The aim of this study was to determine the impact of CS exposure on the phenotype and treatment sensitivity of rodent models of allergic asthma...
May 10, 2018: Respiratory Research
https://www.readbyqxmd.com/read/29725530/long-acting-muscarinic-antagonist-and-long-acting-%C3%AE-2-agonist-therapy-to-optimize-chronic-obstructive-pulmonary-disease-prior-to-lung-cancer-surgery
#4
Takashi Makino, Hajime Otsuka, Yoshinobu Hata, Satoshi Koezuka, Yoko Azuma, Kazutoshi Isobe, Keishi Sugino, Satoru Ebihara, Sakae Homma, Akira Iyoda
Bronchodilators are essential for the perioperative management of patients with chronic obstructive pulmonary disease (COPD) undergoing surgery for lung cancer. The objective of the present study was to examine whether the usage of a long-acting β2-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) could optimize preoperative lung function and reduce the risk for postoperative pulmonary complications. Thirty-two consecutive patients with moderate-to-severe COPD who underwent a lobectomy for lung cancer and received preoperative LAMA (n=19) or LAMA/LABA (n=13) therapy between January 2005 and December 2015 were enrolled in this retrospective study...
May 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29716427/the-safety-of-dual-bronchodilation-on-cardiovascular-serious-adverse-events-in-copd
#5
Paola Rogliani, Josuel Ora, Maria Gabriella Matera, Mario Cazzola, Luigino Calzetta
Introduction Long-acting β2 -adrenoceptor (β2 -AR) agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) is the cornerstone for treating chronic obstructive pulmonary disease (COPD). LABA/LAMA combinations elicit clinical and functional synergistic interaction, and such an interaction should permit to reduce the dose of each monocomponent in the drug mixture to minimize the risk of adverse events (AEs). Overall, currently available LABA/LAMA fixed-dose combinations (FDCs) combine the drugs at the same doses of formulations designed for a single drug...
May 1, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29713156/indacaterol-glycopyrronium-reduces-the-risk-of-clinically-important-deterioration-after-direct-switch-from-baseline-therapies-in-patients-with-moderate-copd-a-post-hoc-analysis-of-the-crystal-study
#6
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Francesco Patalano, Xavier Nunez, Veronica A Pagano, Robert Fogel, Claus F Vogelmeier, Andreas Clemens
Purpose: COPD is a progressive disease characterized by exacerbations and a decline in health status and lung function. Clinically important deterioration (CID) is a composite endpoint used to evaluate treatment efficacy. This analysis evaluated the impact of a direct switch to once-daily indacaterol/glycopyrronium 110/50 µg (IND/GLY) from previous monotherapy with a long-acting β2 -agonist (LABA) or long-acting muscarinic antagonist (LAMA) or with an LABA and an inhaled corticosteroid (LABA + ICS) on reducing CID...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29705779/when-two-drugs-are-better-than-three-re-modulating-the-therapeutic-plan-of-a-chronic-obstructive-pulmonary-disease-patient
#7
Antonella Ielpo, Ernesto Crisafulli
We present the case of a 77-year-old man diagnosed with chronic obstructive pulmonary disease (COPD) stage D with emphysema phenotype and treated with triple therapy (salmeterol, fluticasone propionate, and tiotropium) for 1 year without relevant improvements in exertional dyspnea and disease impact. After switching to combination therapy with a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) (indacaterol/glycopyrronium), we observed, in a 3-month period, a substantial reduction of the modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT) scores...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29670344/cost-effectiveness-analysis-of-a-fixed-dose-combination-of-indacaterol-and-glycopyrronium-as-maintenance-treatment-for-copd
#8
Ming-Cheng Chan, Elise Chia-Hui Tan, Ming-Chin Yang
Objective: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator indacaterol/glycopyrronium (IND/GLY) as a maintenance treatment for COPD patients from the perspective of health care payer in Taiwan. Patients and methods: We adopted a patient-level simulation model, which included a cohort of COPD patients aged ≥40 years. The intervention used in the study was the treatment using IND/GLY, and comparators were tiotropium or salmeterol/fluticasone combination (SFC)...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29668352/once-daily-single-inhaler-triple-versus-dual-therapy-in-patients-with-copd
#9
David A Lipson, Frank Barnhart, Noushin Brealey, Jean Brooks, Gerard J Criner, Nicola C Day, Mark T Dransfield, David M G Halpin, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange, David A Lomas, Fernando J Martinez, Dave Singh, Maggie Tabberer, Robert A Wise, Steven J Pascoe
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2 -agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid-LABA or LAMA-LABA), are uncertain. Methods In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 μg, umeclidinium (a LAMA) at a dose of 62...
April 18, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29650761/once-daily-triple-therapy-inhaler-for-copd
#10
(no author information available yet)
▼Trelegy Ellipta (GSK) is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]) and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]).1 It is licensed for once-daily use as maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Here, we consider the evidence for this combination product and discuss how it fits with current management strategies...
April 2018: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/29629403/effectiveness-of-umeclidinium-vilanterol-for-protocolized-management-of-chronic-obstructive-pulmonary-disease-exacerbation-in-hospitalized-patients-a-sequential-period-analysis
#11
Todd W Chapin, Michael A Mann, Gary L Brown, Traci L Leitheiser, Becky Anderson, David D Leedahl
Background: Bronchodilator therapy is a foundation of chronic obstructive pulmonary disease (COPD) exacerbation treatment. Although international guidelines recommend short-acting formulations given multiple times per day, long-acting formulations have not been adequately evaluated. The objective of our study was to determine the effectiveness of umeclidinium-vilanterol (UME/VIL), long-acting beta2-agonist/long-acting muscarinic antagonist (LABA/LAMA) as a once-daily alternative for treating COPD exacerbations in hospitalized patients...
January 24, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://www.readbyqxmd.com/read/29629401/pattern-and-adherence-to-maintenance-medication-use-in-medicare-beneficiaries-with-chronic-obstructive-pulmonary-disease-2008-2013
#12
Shawn P E Nishi, Matthew Maslonka, Wei Zhang, Yong-Fang Kuo, Gulshan Sharma
Background: Maintenance medications provide symptomatic relief, improve lung function and reduce the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Despite their proven benefits, limited information exists on maintenance medication use and adherence among users. Objective: We examined the patterns and factors associated with the receipt of and adherence to maintenance medication in individuals with COPD. Methods: A retrospective cross-sectional study of 5% of Medicare beneficiaries enrolled in Parts A, B and D with COPD who received maintenance medication from 2008 to 2013 was conducted...
January 24, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://www.readbyqxmd.com/read/29626716/pharmacological-mechanisms-leading-to-synergy-in-fixed-dose-dual-bronchodilator-therapy
#13
REVIEW
Luigino Calzetta, Maria Gabriella Matera, Mario Cazzola
Long-acting β2 adrenoceptor agonists (LABAs) in combination with long-acting muscarinic antagonists (LAMAs) can elicit functional and clinical benefits in chronic obstructive pulmonary disease (COPD). LABA/LAMA combinations synergistically relax human isolated airways at the level of the medium and small bronchi. LABAs and LAMAs both modulate the bronchial tone via different pathways localized at the level of presynaptic parasympathetic fibers and airway smooth muscle cells. The exact nature of the interactions between these pathways is not completely understood, but there is cross-talk at many levels in airway smooth muscle cells that is also regulated by the activity of calcium-activated potassium channels and protein tyrosine kinases...
April 4, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29567116/cardiovascular-safety-profile-of-a-fixed-dose-combination-of-glycopyrrolate-and-formoterol-fumarate-delivered-via-metered-dose-inhaler-using-co-suspension-delivery-technology
#14
Gary T Ferguson, Colin Reisner, James Pearle, Paolo DePetrillo, Andrea Maes, Ubaldo J Martin
BACKGROUND: Glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP), and the long-acting β2 -agonist (LABA), formoterol fumarate (FF), delivered via metered dose inhaler using innovative co-suspension delivery technology. Here we report the results of two studies that examined the cardiovascular safety of GFF MDI. METHODS: The thorough QT (TQT) study was a Phase I, randomized, double-blind, single-dose, crossover study to assess GFF MDI 18/9...
April 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29554174/association-of-inhaled-corticosteroids-and-long-acting-muscarinic-antagonists-with-asthma-control-in-patients-with-uncontrolled-persistent-asthma-a-systematic-review-and-meta-analysis
#15
REVIEW
Diana M Sobieraj, William L Baker, Elaine Nguyen, Erin R Weeda, Craig I Coleman, C Michael White, Stephen C Lazarus, Kathryn V Blake, Jason E Lang
Importance: Long-acting muscarinic antagonists (LAMAs) are a potential adjunct therapy to inhaled corticosteroids in the management of persistent asthma. Objective: To conduct a systematic review and meta-analysis of the effects associated with LAMA vs placebo or vs other controllers as an add-on therapy to inhaled corticosteroids and the use of a LAMA as add-on therapy to inhaled corticosteroids and long-acting β-agonists (LABAs; hereafter referred to as triple therapy) vs inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma...
April 10, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29553450/management-of-chronic-obstructive-pulmonary-disease-exacerbations-at-the-nasser-medical-complex-a-clinical-audit
#16
Maha Al-Faqawi, Yousef Abuowda, Alaa Eldeen Elmassry, Bettina Böttcher
BACKGROUND: The frequency and severity of chronic obstructive pulmonary disease (COPD) exacerbations are the most important determinants of prognosis in COPD. The aim of this study was to assess the management of patients presenting with COPD exacerbations at the Nasser Medical Complex in the Gaza Strip and to compare the management with the Global Initiative for Chronic Obstructive Lung Disease guidelines (GOLD 2015). METHODS: We reviewed the medical records of all patients admitted to Nasser Medical Complex and diagnosed with COPD exacerbation between Jan 1, 2014, and Dec 31, 2016...
February 21, 2018: Lancet
https://www.readbyqxmd.com/read/29548318/clinical-and-economic-impact-of-a-one-year-treatment-with-omalizumab-in-patients-with-severe-allergic-asthma-within-a-drug-programme-in-poland
#17
Karina Jahnz-Różyk, Joanna Lis, Marta Warchoł, Aleksandra Kucharczyk
BACKGROUND: Allergic asthma is the most prevalent phenotype of severe asthma where treatment with omalizumab (OMB) has been proven to be particularly beneficial. In Poland, OMB therapy is available and reimbursed within a drug programme where strict inclusion and exclusion criteria are defined. The objective of this study was to present a descriptive analysis regarding the trends in outcomes (clinical, quality of life, costs) among a cohort of patients who satisfy inclusion criteria for the initiation of OMB treatment and who successfully responded to OMB according to a set of objective criteria...
March 16, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29537340/single-inhaler-triple-therapy-utilizing-the-once-daily-combination-of-fluticasone-furoate-umeclidinium-and-vilanterol-in-the-management-of-copd-the-current-evidence-base-and-future-prospects
#18
Mario Malerba, Matteo Nardin, Giuseppe Santini, Nadia Mores, Alessandro Radaeli, Paolo Montuschi
Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2 -adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' daily symptoms and reduce decline of pulmonary function and acute exacerbation rate. Treatment with all three inhaled drug classes is reserved for selected, more severe, patients with COPD when symptoms are not sufficiently controlled by dual LABA/LAMA therapy and exacerbations are frequent...
January 2018: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/29506504/a-phase-iib-randomized-chronic-dosing-incomplete-block-cross-over-study-of-glycopyrronium-delivered-via-metered-dose-inhaler-compared-with-a-placebo-and-an-active-control-in-patients-with-moderate-to-severe-copd
#19
Edward M Kerwin, Selwyn Spangenthal, Christine Kollar, Earl St Rose, Colin Reisner
BACKGROUND: Long-acting muscarinic antagonist (LAMA) and long-acting β2 -agonist (LABA) bronchodilators are key to the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). This Phase IIb study investigated the safety and efficacy of four doses of the LAMA glycopyrronium (GP) delivered using co-suspension delivery technology via metered dose inhaler (MDI). The study was part of a wider clinical trial program performed to determine the optimal dose of GP MDI, the LABA formoterol fumarate dihydrate (FF) MDI, and glycopyrronium/formoterol fumarate dihydrate (GFF) MDI fixed-dose combination to be taken forward into Phase III studies...
March 5, 2018: Respiratory Research
https://www.readbyqxmd.com/read/29505318/a-safety-comparison-of-laba-lama-vs-laba-ics-combination-therapy-for-copd
#20
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani, Mario Cazzola
LABA+LAMA and LABA+ICS combinations are key pharmacological approaches to the treatment of COPD. However, both combination types can induce adverse events (AEs). Areas covered: Current literature on LABA+LAMA and LABA+ICS combinations has been reviewed with a specific focus on their safety profile in the treatment of COPD. Expert opinion: Several meta-analyses have compared the pooled safety data from randomized clinical trials (RCTs) of LABA+LAMA combinations with LABA+ICS combinations. LABA+LAMA caused significantly less AEs and SAEs...
May 2018: Expert Opinion on Drug Safety
keyword
keyword
71589
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"